Summer Sale
50% off Premium Yearly
NASDAQ:ASND
Ascendis Pharma (ASND)
Financials 
Technical Analysis 
Jun 15, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Ascendis Pharma (ASND-Q) has made a notable impact in the healthcare sector, reflecting a strong performance as evidenced by its recent profitability last quarter. With a remarkable 50% increase in its stock price this year, investors are taking notice of its promising trajectory. The company's innovative technology, which extends the half-life of drugs, positions it strategically in a competitive market. As a result, some experts see significant potential for future growth, especially as healthcare continues to evolve. This positive outlook encourages a bullish sentiment among those overweight in healthcare investments.
- «
- ‹
- 1
- ›
- »
Ascendis Pharma (ASND) Frequently Asked Questions
What is Ascendis Pharma stock symbol?
Ascendis Pharma is a American stock, trading under the symbol ASND (previously ASND-Q on Stockchase) on the NASDAQ (ASND). It is usually referred to as NASDAQ:ASND or ASND
Is Ascendis Pharma a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on ASND (previously ASND-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Ascendis Pharma .
Is Ascendis Pharma a good investment or a top pick?
Ascendis Pharma was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Ascendis Pharma .
Why is Ascendis Pharma stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Ascendis Pharma .
Is Ascendis Pharma worth watching?
Ascendis Pharma is covered by Stockchase experts and is worth watching.
What is Ascendis Pharma stock price?
On 2026-06-15, Ascendis Pharma (ASND) stock closed at a price of $222.35.
It reached profitability last quarter and is up 50% this year. Their technology extends the half life of drugs. She just bought it. She's overweight healthcare.